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Summary The Second Meeting of the British Society for Immunology Tumour Immunology Affinity Group (TIAG) took place at King's College
(London, UK) on 17-18 June 1997 and brought together over 100 tumour immunologists from the UK and abroad. In contrast to previous
meetings the focus of the meeting was on the role of adhesion in immunosurveillance and tumour dissemination. In addition, recent
achievements in the areas of chemokines, cytotoxic T-lymphocyte (CTL) and natural killer (NK) cells, co-stimulation, gene and adoptive
immunotherapy were also addressed. The purpose of this report is to outline current trends in tumour immunology.
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ADHESION AND CHEMOTAXIS
The conference began with an overview ofcell adhesion molecules
in the interaction of leucocyte and tumour cells with the endothe-
lium (Dr N Hogg, London, UK). Well-known adhesive ligands
were described including PSGL-1 (a ligand for all three selectins,
especially relevant for neutrophil adhesion), CD44 [as a rolling
receptor for haematopoietic (DeGrendele et al, 1996) and poten-
tially non-haematopoietic cells, such as pancreatic carcinoma and
melanoma] and a4p1 (adherence receptor for leucocytes and
tumour cells) (Figure 1). The role of cell adhesion in leucocyte
activation ('in/out' signalling) was also highlighted. Furthermore,
chemokines, with few exceptions (Szabo et al, 1997), appear
unable to activate adhesion molecules (such as LFA-1) on non-
primed T lymphocytes, as 'naive' T cells do not express corre-
sponding chemokine receptors. However, the adhesion molecules
on activated leucocytes can be 'switched on' if chemokine recep-
tors are cross-linked (e.g. the cross-linking ofIL-8 receptors by IL-
8 bound to extracellular matrix proteins). N Hogg also discussed
the ability of the a4,Bl integrin complex to either facilitate
(Matsuura et al, 1996) or inhibit (Qian et al, 1994) the metastasis of
neoplastic cells by decreasing the invasive potential of melanoma
and even by inducing apoptosis oflymphoma cells (ifexpressed in
situ). Furthermore, additional studies described the ability of the
metalloproteinase MMP2 to form a complex with aVP3 integrin
(vitronectin R) (Brooks et al, 1996) and facilitate melanoma cell
migration through its ability to digest collagen, unveiling its hidden
RGD sequence and thus permitting integrin-mediated adhesion. In
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another model, the urokinase-type plasminogen activator receptor
(uPAR) forms acomplex with active integrins, which has the effect
of destabilizing integrin adhesion and promoting adhesion and
migration on vitronectin, thus potentially enhancing the invasive
properties oftumour cells (Wei et al, 1996).
The adhesion and trafficking mechanisms of lymphocyte trans-
migration in both normal and adjacent tumourendothelium remain
poorly understood. In an elegant in vivo model using a mouse
cremaster muscle implanted with a tumour and fluorescent
confocal microscopy, murine lymphocytes were examined for
their ability to traffic into tumour-bearing tissues (Dr N Brown,
Sheffield, UK). Quite unexpectedly, IL-2-activated T cells and
lymphocytes from previously immunized but not naive animals
appeared to be 'trapped' by endothelium adjacent to tumour. This
local arrest/extravasation could be partly blocked by the use of
antibodies specific forVLA-4 and VCAM, confirming an involve-
ment of these integrin molecules in the trafficking event rather
than a purely mechanical non-specific homing mechanism.
An elegant in vitro model of lymphocyte migration from blood
to lymph node (involving transmigration of lymphocytes through
high endothelium cells) also demonstrated the role of VLA-
4NVCAM-1 in the lymphocyte trafficking process (Dr A Ager,
London, UK). Although blocking of LFA-1/ICAM-1 interactions
alone did not affect the T-cell transmigration, when combined with
blockofVLA-4NCAM-1 interactions, lymphocyte movement was
almost totally abolished. Freshly isolated CD4+ and CD8+ T cells
as well as B lymphocytes but not lymphoma cells (WEHI, Jurkat)
behaved similarly in these assays. Interestingly, the inhibition of
L-selectin shedding through the use of the zinc-dependent matrix
metalloproteinase inhibitor Ro 31-9790 also prevented the lympho-
cyte migration. Additional studies also revealed the existence of a
novel, phorbol ester inducible, metalloproteinase (L-selectin shed-
dase) responsible for the L-selectin shedding (Preece et al, 1996).
The biology of the recently discovered CD31 molecule was
outlined by D Simmons (Oxford, UK). CD31 can be detected on a
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Figure 1 Possible mechanisms of tumour cell extravasation. While the
mechanisms by which leucocytes migrate from the vascular space into
surrounding tissues are well characterized, much less is known of the
extravasation of metastasizing tumour cells. However, studies of various
tumour cell lines suggest that they use similar cell-surface molecules to
mimic at least some of the leucocyte adhesion mechanisms. Despite such
similarities with leucocytes, the complete sequence of events leading to
trans-endothelial migration of any one metastasizing cell type will depend on
its unique adhesive repertoire, and is yet to be determined. aGiavazzi et al
(1993). bMatsuura et al (1996). cBrooks et al (1996). dWei et al (1996)
Table 1 Members of the C-X-C, C-C and C chemokine superfamily
C-X-Ca C-C C
---C-X-C--C-Cb-- -C-C--C-C-- -C------C-
Humanc Mousec Human Mouse Human Mouse
4ql2-21d - 17qll-21 11 - 1
IL-8/NAP-1 - MCP-i JE Ltn Ltn
GCP-1 MCAF
GROa KC MCP-2 MCP-2 - ATAC
MGSA
GRO,B MIP-2 MCP-3 MCP-3 - -
MIP2a
GROy - MCP-4 - - -
MIP2P
ENA78 ENA78 MCP-5 - - -
NAP-2 - RANTES RANTES - -
NAP-4 - MIP-ila MIP-la -
LD78
GCP-2 - MIP-1ip MIP-1i - -
ACT2
PF-4 PF-4 pAT44 - - -
IP-10 IP-10/C7 1309 TCA-3 - -
CRG-2 p500
Mig Mig - Cio - -
MRP-1
- - - MRP-2 - -
- - HCC-1 - - -
aSubfamily. bStructure. cSpecies. dChromosome.
number ofcell populations, including endothelium, T lymphocytes
and monocytes, and is capable of facilitating both homophilic
(when it functions as a gatekeeper and provides tissue integrity) or
heterophilic adhesion interactions (through axV,3). Further studies
revealed that homophilic adhesion of CD31 molecules constitutes
a dimer; however, in contrast to the ICAMs, all domains ofCD31
are required for this interaction. Once endothelium is activated,
CD31 can also act as a heterophilic adhesion molecule facilitating
the transmigration ofleucocytes.
Like CD31, the junction adhesion molecule (JAM) is also a
member of the Ig superfamily but contains only two domains and
no glycosylation sites (Dr D Simmons). JAM was initially identi-
fied by its unique pattern ofexpression in endothelial and epithe-
lial celljunctions and was found to have splice variants. Similar to
CD31, it can also support the migration of neutrophils and mono-
cytes. Despite the fact that JAM-mediated adhesion is thought to
be cation and cytoskeleton dependent, the ligand for JAM has not
yet been found. Little if anything is presently known about the
expression of CD31 and JAM within tumour sites. Similar to
cadherins, which are also involved in the maintenance of tissue
integrity, these new adhesion molecules are expected to play an
important role in tumour biology (Charpin et al, 1997).
In addition to adhesive interactions, chemokines also play an
important role in the trafficking (Taub and Oppenheim, 1994;
Taub, 1996) of a variety of immunocompetent cells (Table 1; Dr
DD Taub, Baltimore, MD, USA). Chemokines are a family oflow-
molecular-weight peptides that have from 20% to 70% amino acid
homology and are related by a conserved motif containing four
cysteine residues. The chemokine superfamily is separated into
four distinct families (C-X-C, C-C, C, C-X-X-C) based on their
chromosomal localization, primary and secondary structures, and
the placement and spacing of conserved cysteine motifs. Each of
these chemokines has been shown to induce the directional migra-
tion of selected cell types, including granulocytes, monocytes and
lymphocytes (Table 2). In addition, many tumours can also consti-
tutively secrete or be induced to express these chemotactic
molecules. While the biological relevance of tumour-produced
chemokines remains obscure, studies have revealed that several
chemokines can stimulate tumour cell growth in an autocrine
manner (e.g. IL-8 and melanoma). In addition, several C-X-C
chemokines have been shown to possess either angiogenic (IL-8)
or angiostatic (IP-1O) activities, which appear to modulate tumour
growth in vivo. Alternatively, constitutive chemokine production
by certain tumour cells has been suggested to break down the local
chemokine gradient and, by this means, inactivate chemotaxis of
immune cells into various tissues or tumour sites (Dr DD Taub).
In general, it is worth noting that the detection of a chemokine by
immunoassay most likely reflects its biological activity as no natural
antagonists or neutralizing autoantibodies have yet been clearly
identified. Furthermore, it has also been shown that the mere pres-
ence ofchemokine receptors on the surface ofa cell population does
not necessarily render these cells responsive to soluble chemokine
ligands (e.g. IL-8 and NK cells) (Taub and Oppenheim, 1994; Taub,
1996). In addition, extensive examination of chemokine subfamily
effects on a wide panel of human and murine T-cell clones has
demonstrated a differential ability to migrate and adhere to adhesive
ligands in response to various chemokines, despite the fact that
many ofthese clones were derived from the same donor under iden-
tical conditions. Finally, chemokines appear to not only modulate
leucocyte trafficking and adhesion but also contribute to T-cell co-
stimulation and IL-2 production, cytotoxic T-lymphocyte (CTL)
degranulation and cytolysis, induce B7 co-stimulatory molecule (P-
chemokines) on antigen-presenting cells (Taub et al, 1996a) and, in
certain cases, may even direct T-cell responses towards either Th2
(MCP-1) or ThI responses (MIP-ax).
An in vivo correlation between MCP-1 expression and the infil-
tration of ovarian tumours by CD8 lymphocytes (accompanied by
CD45+ cells and monocytes) was reported by RPM Negus
(London, UK). Local fluctuations of oxygen tension have been
suggested to affect MCP-l production by carcinoma cells and the
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Table 2 In vitro effects of chemokine family members on leukocytes






Increased adhesion to endothelial cells, fibrinogen and ECM
Increased killing of micro-organisms
Increased expression of CD11a, CD11b, CD11c and CD18
Increased lysosomal enzyme release
T lymphocytes Chemotaxis (CC, C and CXC)
Stimulated polyphospoinositide hydrolysis
Increased adhesion to endothelial cell monolayers and ECM
Increased metalloproteinase release




TILs Chemotaxis (CC, CXC and C)
Increased degranulation
B lymphocytes Chemotaxis (CXC and C)
Inhibits IL-4-induced IgE production
Increases B7 expression
Increased immunoglobulin secretion
Increased B cell proliferation
NK cells Chemotaxis (CC and CXC)
Increased adhesion to endothelial cell monolayers and ECM
Increased killing of tumour targets
Increased degranulation
Increased adhesion to extracellular matrix proteins






Eosinophils Increased superoxide anion release (CC and CXC)
Increased cytosolic Ca++
Induced cationic protein release
Increased adhesion to endothelial cells and ECM
Increased N-acetyl-b-glucuronaminidase
Increased cytostatic augmenting activity
Increased intracellular calcium
Induced arachondonic acid release
Increased cell surface CD11a/CD18
Mast cells Chemotaxis (CC and CXC)
Increased histamine release
Dendritic cells Chemotaxis (CC)
See also Taub (1996).
distribution of infiltrating immunocompetent T cells in situ.
Similarly, using an in vivo model ofhuman T-cell migration (injec-
tion of human chemokines into the ear of SCID mice repopulated
with human lymphocytes) has been successfully used to demon-
strate both direct (o chemokines) and indirect (IL-8) roles for
chemokines in mediating lymphocyte transmigration and engraft-
ment (Dr DD Taub).
NK AND CTL RESPONSE
L Moretta (Italy) outlined acontemporary understanding ofnatural
killer (NK) cells and theirtarget recognition mechanisms. NK cells
have been shown to use a repertoire ofkiller-cell inhibitory recep-
tors (KiR orNKiR) to sense loss ofMHC class I molecules (Lanier
and Phillips, 1996; Lopez-Botet et al, 1996). Examination of NK
cell clones has demonstrated that the NKcell populations arequite
heterogeneous and that every cell expresses, at least, one of KiR
(though a coexpression may also occur). The mechanism of KiR
recognition is so sophisticated that even a single allele loss (with a
single amino acid residue substituted) can be recognized. This is
very convenient because ofthe ability ofmany tumours (e.g. carci-
nomas) to lose HLA expression, including losses of single HLA
alleles. Furthermore, IL-15 has been shown to play an important
role in the maturationofCD94+ NKcells (Mingari etal, 1997) and
induction offunctionally active CD94/NKG2A receptors on CD8+
T lymphocytes (Mingari et al, submitted). Indeed, a small propor-
tion of T cells (both a,B and y8, but mostly CD8+) have been
shown to express KiR and lyse targets in NK-like fashion. These T
lymphocytes express memory cell phenotypes and are represented
by oligoclonal or monoclonal populations (Mingari et al, 1996).
These populations are believed to expand after prolonged antigen
stimulation to prevent an autoimmune response. In support ofthis
theory, CTL lysis of human immunodeficiency virus (HIV)-
expressing targets has been improvedby masking KiR interactions
with monoclonal antibodies. Following an earlier observed corre-
lation between the expression of B7- and NK-mediated killing
(Azuma et al, 1992), J Galea-Lauri (London, UK) convincingly
demonstrated CD28 but not CTLA-4 or B7-1 expression on
peripheral blood CD3-CD56+CD16+ lymphocytes. This CD28
expression varied from minimal to abundant depending on the
human donor used. In addition, C-C chemokines have been shown
to bind to and chemoattract human NK cells and NK cell clones
(Dr DD Taub) (Taub et al, 1996b). Several of these chemokines
also promoted NK cell killing and cellular degranulation.
However, the biological significance of chemokines on NK cells
activities has not yet been described.
Using a highly sensitive reverse transcription polymerase chain
reaction (RT-PCR) method, it has been possible toquantify tumour
infiltrating lymphocytes (TILs) expressing different T-cell recep-
tors (TCR) V regions in tumour biopsies (Dr J Zeuthen, Denmark).
The TCR repertoire of TILs appeared to be skewed (indicating a
clonal or oligoclonal T-cell expansion) and reproducibly differed
between primary and metastatic melanoma lesions (Scholler et al,
1994). Furthermore, similar changes have been observed in
regressing and non-regressing parts of the same primary
melanomas, suggesting the presence of different T-cell repertoires
(thor Straten et al, 1996). In an effort to understand why specific
parts ofthe same tumourbehave differently, it would beinteresting
to analyse the in situ cytokine production of primary and
metastatic lesions. Surprisingly, the induction of HLA-DR on
melanomas by IFN-y has correlated with their escape from CTL
surveillance (Kirkin et al, 1996). A similar adverse effect has been
also reported in one clinical trial; however, in another trial, the
systemic administration of IFN-y was found to restore lost HLA
class I expression (Dr A Knuth, Frankfurt, Germany). In the
former case, HLA-DR may play a 'reporter' role of unrelated
phenotypical changes in melanoma (e.g. FAS ligand (FAS-L)
induction). Notably, the CTL-mediated killing of an immunogenic
melanoma could be improved by the antibody-mediated neutral-
ization ofFAS-L (Dr J Zeuthen).
A prolonged vaccination with HLA-A2-restricted peptides
derived from tumour-associated antigens (Melan A, tyrosinase,
gplOO) produced encouraging results in patients with progressive
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stage 4 melanoma. Seven out of 12 patients whose melanomas
were progressing achieved stable disease post vaccination (Table
3; Dr A Knuth). All patients developed delayed type hypersensi-
tivity (DTH) and CTL responses to at least one peptide (tyrosi-
nase, Melan A and influenza). Improved DTH responses were
observed with the addition of intradermal granulocyte-
macrophage colony-stimulating factor (GM-CSF) administration.
Furthermore, immunohistochemical analysis showed an intensive
infiltration of biopsies (CD4+, CD8+, CDla+, HLA DR+) and a
THI type immune response (IFNy+, TNFa+, IL-4-, IL-IO-). At
the same time progressive disease was associated with a local loss
of antigen (Melan A, tyrosinase) and/or HLA class I expression.
The use of polyvalent vaccines (to avoid a selection of antigen-
loss variants) combined with certain cytokines (similar to IFN-y in
their ability to up-regulate MHC class I expression) as well as an
optimizatioi,.of the dose and route of delivery of these specific
therapies has been suggested for future protocols.
M Adams (Cardiff) reported on the successful propagation of
dendritic cells (DCs) from peripheral blood of healthy donors and
patients by IL-4 and GM-CSF. The DCs obtained could be loaded
with peptides (HPV 16 E7, HER-2-Neu) and subsequently
generate specific CTLs. Unfortunately, DCs expanded from four
patients with cervical cancer did not express CDla, even though
they expressed similar levels of MHC class II, CD80 (B7-1) and
CD54 (ICAM-1). Interestingly, when patients' DCs were used to
generate CTLs in vitro the resulting CTL response was defective
compared with that achieved with DCs obtained from normal
healthy volunteers. Further studies are required to unravel the
basis of this defective response and how it might be corrected. E
M-L Evans (Cardiff, UK) identified HPV 16 E7-specific CTLs in
peripheral blood (four out of five), draining lymph nodes (two out
ofthree) and tumours (one out of three) ofcervical cancer patients
but not healthy donors. Notably, in all patients tested, the
frequency of HPV-specific CTLs was higher in lymph nodes and
tumour tissue compared with peripheral blood. J Saba (Sheffield,
UK) showed that it is possible to generate CTLs to the HLA-A2-
restricted peptides for the melanoma antigens (Melan A, tyrosi-
nase and gplOO) from the peripheral blood of ocular melanoma
patients using a bulk culture method that uses a maximum of60 ml
ofblood. CTL were generated to all peptides in a donor-dependent
fashion and, if a response to tyrosinase was generated, these CTLs
were always the most potent cytolytic cells compared with those
generated to other antigens.
LG Durrant (Nottingham, UK) reported on studies mapping the
helper T-cell epitope within the 105D7 vaccine, an anti-idiotype
antibody that mimics the 79Tgp72 antigen, which is overexpressed
on colon carcinomas. The corresponding CDRH3 peptide (HLA
DR1, -3 and -7 binding motifs) stimulated T-cell proliferation from
naive donors (eight out ofeight ofpermissive haplotype) and could
prime them to respond to both 105AD7 or 791Tgp72 positive cells,
although the response to the whole Ag (105AD7) was much
stronger. In addition, a DNA vaccine incorporating heavy- and
light-chain variables of 105AD7 antibody has been produced and
shown in preliminary experiments to induce antibody production
in a mouse model (Dr V Potter, Nottingham, UK).
GENE AND ADOPTIVE IMMUNOTHERAPY
Cancer gene therapy is intended to improve host immunosurveil-
lance pathways that a tumour may evade through a number of
mechanisms. These include decreased immunogenicity (e.g.
Table 3 Response of stage 4 melanoma patients immunized with polyvalent
peptide vaccine
Clinical response Treatment with Treatment with
peptides peptides and
intradermal GM-CSF
Complete response 1/12 2/16
Partial response 1/12 2/16
Stabilization of disease 7/12 7/16
Progression of disease 3/12 5/16
down-modulation of HLA class I molecule or antigen expression);
suppression of the immune system (e.g. up-regulating FASL on
tumour and FAS molecules on effector cells); the loss of the TCR
zeta chain or DNA binding molecules in T cells obtained from
tumour-bearing hosts; and the stimulation of tumour growth and
increased angiogenesis (Dr R Vile, London, UK). A fine equilib-
rium between tumour growth and suppression can be shifted (we
all hope) by improving/restoring a number of links in the chains of
the immune response (Chong and Vile, 1996). The successes
initially achieved with transfer of IL-2, IL-4 or, later, B7 genes
could be explained by bypassing 'the helper arm' and directly acti-
vating CD8 and possibly NK cell responses. In contrast, recent
success with GM-CSF gene transfer to tumour cells is probably a
result of the recruitment and activation of antigen-presenting cells.
Several ofthe approaches tested to date have yielded tumour rejec-
tions and, on some occasions, systemic and, most importantly,
long-lasting immunity (Chen et al, 1997). While there is a worry-
ingly long list of successes achieved using many cytokine or co-
stimulatory genes (Forni and Foa, 1996), this does not mean that
any cytokine transfection can cure cancer but rather reflects the
situation that, for any given tumour (model), a particular co-stimu-
latory combination can be found (or adjusted). However, this does
not necessarily echo the situation in patients. Perhaps it is time to
stop and think about the mechanisms involved in the generation of
an anti-tumour response rather than plunge straight into clinical
trials.
Gene therapy offers a number of approaches to fighting various
tumours. We can attempt to convert tumour cells to antigen-
presenting cells by making them more immunogenic (B7 co-stim-
ulation); restore lost MHC molecules; transfect with cytokines
capable of a direct stimulation of lymphocytes (IL-2) or even
enhance tumour antigen release and its subsequent up-take by
professional antigen-presenting cells (presuming that antigen-
specific T cells are still in the circulation or can be generated from
naive precursors). The last approach also conforms with a recently
suggested 'Danger Model' (Ridge et al, 1996) theory according to
which induced necrosis may attract antigen-presenting cells
(macrophages, dendritic cells), increase their up-take and the
subsequent delivery of antigen in an appropriate fashion to T
lymphocytes. The recruitment of antigen-presenting cells can be
further potentiated by the local production of GM-CSF or IL-12.
Based on this rationale and supporting data obtained from animal
models, this group hopes to progress to clinical trial in patients
with melanoma using retrovirus incorporating the HSV-TK and
GM-CSF genes and a tumour-specific promoter/enhancer (e.g.
tyrosinase).
A successful effect (50% complete remission) of locally deliv-
ered co-stimulatory IL-12 on the growth of otherwise fatal
mesothelioma appeared to correlate with the infiltration oftumour
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with CD4+ and CD8+ lymphocytes (Dr RA Lake, Australia).
However, it remains to be established whether there is a connec-
tion between IL-12 secretion and the induction of heat shock
proteins, as the latter also had a beneficial effect in this tumour
(Alexandroff and Dalgleish, 1997). Furthermore, a phase I clinical
trial was conducted in patients with mesothelioma using a replica-
tion-defective Vaccinia virus containing cDNA for IL-2 (Dr RA
Lake). This trial demonstrated that intralesional administration of
the viral construct is safe and non-toxic and results in intratumoral
expression ofIL-2 for up to 1 week.
AL Barnard (London, UK) reported on the development of a
semisyngeneic melanoma vaccine that may be convenient for clin-
ical use. Also, possible difficulties in the expansion oftumourfrom
a cancer patient or finding acompletely HLA-matched tumour and
encouraging results recently reported about the use of allogeneic
melanoma vaccines should be kept in mind when pondering a
potential vaccine (Knight et al, 1996). In the developed hybrid
model, the combined transfection with B7.1 and IL-2 demonstrated
a beneficial anti-tumour effect. In this respect, a stimulatory effect
ofbladder cancer cells on the proliferation ofallogeneic peripheral
blood lymphocytes was observed (Dr AB Alexandroff, Edinburgh,
UK). The observed stimulatory effect correlated with tumour cell
expression of CD40, ICAM-1, -2 and cytokine production (IL-6)
but not B7 or CD40L expression. Ofnote, addition ofrecombinant
CD40L to bladder or pancreatic carcinoma cell lines markedly up-
regulated expression of ICAM-1 and FAS as well as stimulated
production of IL-6 but not IL-4, IL-10 or IL-1. Furthermore, FAS
expression could also be enhanced by treatment with IFN-y and
TNF-ax. These findings may shed some light on the recently
reported role of CD40L in the protective immunity induced by
tumour vaccines (Mackey et al, 1997). FAS and FAS-L coexpres-
sion was also observed on normal breast epithelial cells, while
many breast carcinoma cells appear to lose FAS but continued to
express FAS-L (Dr CB Ragnarsson, Reykjavik, Iceland). Overall,
the expression of FAS-L has been reported on a number of
neoplasms constitutively or after chemotherapy and has been
suggested to play an important role in evasion of immuno-
surveillance (Strand et al, 1997; Walker et al, 1997).
Because of a high rate of relapse and an acquired resistance to
chemo- and radiotherapy, bone marrow transplantation (BMT)
remains a therapy of choice for a number ofhaematological malig-
nancies, including chronic and acute myeloid leukaemia (CML,
AML), myelodysplastic, syndrome, etc. Although allogeneic BMT
has been shown to have adverse effects (e.g. liver and FAS-L-
mediated skin damage), in studies on a large number ofpatients in
Europe and North America, these transplants have been shown to
have a lower relapse rate compared with syngeneic BMT. While the
precise mechanism ofthis advantage is nottotally clear, the immune
response ofdonor T lymphocytes against residual malignant cells is
believed to play an important role in these transplants (Dr E Fuchs,
USA). These results have been confirmed, on the one hand, by an
inverse correlation between graft vs host (GvH) disease and relapse
rate and, on the other hand, by an increased relapse after T-cell
purging ofdonor BMT (up to fivefold in CMLs). Similarly, positive
effects have been observed in an animal BMT model. CML cells are
notorious fortheirresistance toboth chemotherapy andradiotherapy
as a result ofthe induction ofthe p2.I0 fusion protein (a product of
bcr-abl) and a frequent p53 mutation. However, it appears that,
while a pre-B cell line may acquire resistance to chemo- and/or
radiotherapy after transfection with p2.10 fusion protein, it still
remained sensitive to CTL-mediated lysis. Moreover, thymocytes
derived from p53-deficient mice remain readily susceptible to both
Fas- and CTL-mediated apoptosis, but are no longer sensitive to
radio- and chemotherapy-induced apoptosis. These findings give
clear incentives for an immunological approach towards improving
allogeneic BMT. Indeed, the infusion of donor T cells to CML
patients during blast crisis induced a long-lasting remission (2-5
years) in 62% ofthe patients. Additional experiments have demon-
stratedthat, intheCMLmodel, purifiedB cellsprovided a 'survival'
(possiblybclXlassociated) ratherthan a 'proliferative' co-stimulatory
signal to T lymphocytes. However, this effect can be reversed using
spleen cells, containing dendritic cells. Based on these data, a clin-
ical adoptive immunotherapy trial involving co-transfusion ofdonor
Tcells andrecipientdendritic cells has been envisaged. Therecently
reported fusion of dendritic and tumour cells (Gong et al, 1997) as
well as the immortalization ofdendritic and folliculardendritic cells
open up further perspective oftheiruse in immunotherapy.
CONCLUSIONS
This short meeting has highlighted some important new develop-
ments in areas related to tumour biology as well as pointing to new
directions for the future. Progress has been made in the characteri-
zation of some of the molecules involved in cell attachment and
migration (ofboth immune cells and tumourcells), yet furtherwork
is required to fully elucidate the mechanisms involved, together
with the role of cytokines and chemokines in these processes. NK
cells and CTLs are also involved in tumour cell destruction but the
recognition and cytolytic mechanisms mediating these responses
are unclear. Nevertheless, tumour antigen-based vaccines, in the
form ofpeptides, have shown promising results with future studies
being planned incorporating different combinations of peptides or
whole antigen molecules in combination with cytokines or
immunological adjuvants. Clearly, while advances have been made
in understanding the factors involved in leucocyte trafficking and in
gene and immunotherapy of cancer, efforts are still needed in all
these areas and, until we have a more thorough understanding ofall
the processes involved in these arenas, no appropriate and effective
prevention and treatment ofcancer will be available.
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